window.addEventListener('load', function () { // Fire a synthetic scroll event window.dispatchEvent(new Event('scroll')); });Skip to main content

Virus Neutralization Assays

With Laser Force Cytology™

A virus neutralization assay measures how well an antibody or serum sample reduces or prevents viral infection in cells. Teams use it to assess vaccine response, characterize neutralizing antibodies, and support potency testing in development and quality control.

The Challenge: Slow, Variable, and Indirect Neutralization Assays

Virus neutralization assays are foundational to vaccine development, potency assessment, and immune-response characterization. Yet conventional methods, including the plaque reduction neutralization test (PRNT) and microneutralization assays, are time-consuming, labor-intensive, and limited in throughput, and results often depend on subjective plaque or cytopathic effect readouts.

Many of these assays rely on plaque formation, overlay media, reporter constructs, or fluorescent labels. That adds assay development time, calls for multiple serum dilutions, and slows decisions, a particular problem for new and emerging viruses where labeled reagents may not exist yet. As vaccine platforms diversify, teams need faster, more objective, and more reproducible ways to quantify neutralizing activity.

Speak To An Expert

How Radiance® Transforms Virus Neutralization Assays

Laser Force Cytology™ (LFC™), the analytical engine behind Radiance®, enables a label-free, single-cell approach to virus neutralization assays. Instead of counting plaques or waiting on reporter signals, Radiance® measures the biophysical and biochemical changes that infection causes in individual cells, then quantifies how much a serum or antibody sample reduces that infection.

The result is a cell-based neutralization assay that delivers results similar to PRNT, with less time and labor and no overlay medium to optimize.

Key Advantages of Radiance® for Neutralization Assays

Shorter time to result: a shorter incubation than PRNT, followed by a 5-minute automated instrument read
Label-free measurement: no reporters, dyes, or antibody labels, which shortens assay development for new and emerging viruses
Single-cell resolution: 40+ parameters measured per cell, at the level where infection actually occurs
Fewer serum dilutions: a larger dynamic range means fewer dilutions per sample
Objective, quantitative results: automated capture and analysis replace manual plaque counting
Simple workflow: 10-minute sample prep, a 96-well plate format, and minimal reagent requirements
Standalone assay: no need to correlate results to your current method

Radiance® gives teams a more direct, objective read on neutralizing activity, supporting faster development cycles and stronger lot-to-lot and site-to-site comparability.

Applications Across Vaccine Development and QC

Radiance® supports neutralization and potency workflows across vaccine R&D, process development, and quality control.

  • Virus neutralization assay development and optimization
  • Vaccine potency assay characterization and comparability
  • Neutralizing antibody assay development for clinical and preclinical studies
  • PRNT assay replacement or orthogonal confirmation
  • Live-virus neutralization testing alongside pseudovirus neutralization assays
  • Seroneutralization profiling for vaccine response monitoring
  • Antiviral compound screening
  • Functional characterization that supports fit-for-purpose potency and neutralization assays

Radiance® strengthens potency and neutralization analytics across development and QC, with consistent, fit-for-purpose data.

Speak To An Expert

Functional Insight That Drives Better Decisions

Traditional neutralization assays measure late-stage outcomes such as plaque formation, reporter expression, or cytopathic effects. Radiance® measures changes in the infected cells themselves, enabling:

  • Earlier detection of neutralizing activity
  • Quantitative, operator-independent potency data
  • Better lot‑to‑lot and site‑to‑site comparability
  • Reduced reliance on engineered reporters
  • Functional data that supports regulatory expectations for fit-for-purpose assays

By measuring how cells actually respond to infection, Radiance® provides a more direct and predictive view of vaccine performance.

PRNT vs. Laser Force Cytology™ Neutralization Assays

Here is how an LFC neutralization assay on Radiance® compares to a traditional plaque reduction neutralization test.

Factor PRNT LFC neutralization assay (Radiance®)
Readout Manual plaque counting Automated, label-free single-cell measurement
Incubation Several days while plaques form Shorter incubation than PRNT
Overlay medium Required and must be optimized Not required
Serum dilutions Many dilutions per sample Fewer, due to a larger dynamic range
Labels and reagents Staining needed to visualize plaques No labels or antibodies
Hands-on labor High Reduced
Results Subject to operator interpretation Quantitative and objective

Zika Virus Neutralization Using Laser Force Cytology™

This technical note shows how Radiance® measures Zika virus neutralization, without labels, using serum with a known neutralizing antibody. The study highlights:

  • A Radiance® Infection Metric that separates virus-only wells from serum-treated and uninfected control wells
  • A dose-dependent neutralization curve across 1:10, 1:100, and 1:1000 serum dilutions
  • Shorter time to detection than conventional methods
  • Reduced labor and fewer dilutions
  • Minimal reagent and antibody requirements, which matters for emerging viruses where reagents may not exist yet

Together, these results show how Radiance® provides a faster, label-free alternative to PRNT for quantifying neutralizing activity.

Request the technical note

Radiance® for Modern Vaccine Development

Vaccine programs now span viral vectors, mRNA, and recombinant platforms, and each one needs fast, reproducible, function-based neutralization assays.

Laser Force Cytology™ is an established method, with:

  • Testing across 40+ viruses and 50 cell types
  • Measurements published in ISO 16921-2 (viral vector quantification) and ISO 8934-1 (cell viability)
  • Use in ATCC® adenovirus reference material Certificates of Analysis for viral infectivity
  • 21 CFR Part 11 compliant software (Illuminate™ and ReportR™) for regulated labs
  • A 96-well plate format for unattended, automated analysis

Radiance® helps teams move from slow, subjective assays to rapid, functional analytics that support development, process monitoring, and lot release.

Virus Neutralization Assay FAQs

What is a virus neutralization assay?

A virus neutralization assay measures how well an antibody or serum sample reduces or prevents viral infection in cells. It is used to evaluate vaccine response, characterize neutralizing antibodies, and support potency testing.

How does an LFC neutralization assay compare to PRNT?

LFC-based neutralization assays provide results similar to the plaque reduction neutralization test (PRNT), with a shorter incubation, less hands-on labor, fewer serum dilutions, and no overlay medium to optimize.

What sample format does Radiance® use?

Radiance® uses a 96-well plate format with up to 200 µL per well and analyzes both adherent and suspension cells.

How long does sample preparation take on Radiance®?

Sample prep takes about 10 minutes, and the instrument time to result is 5 minutes. Total assay time also includes the infection incubation, which is shorter than for PRNT.

Can LFC neutralization assays be used for new or emerging viruses?

Yes. No antibody labeling is needed, so teams can build assays for emerging viruses without waiting for labeled reagents. LFC has been tested across more than 40 viruses.

Does Radiance® require labels or reporter viruses?

No. Laser Force Cytology™ measures the intrinsic biochemical and biophysical properties of each cell, so neutralization assays run without dyes, antibody labels, or engineered reporters.

Move Faster With Functional Neutralization Insight

Radiance® gives teams a faster, label-free view of how viral infection is inhibited at the single-cell level, helping accelerate vaccine development and strengthen potency assessment.

Speak To An Expert
Close Menu